Global Fragment-based Drug Discovery Market Investigation and Growth Forecasted until the End of 2023

Market Research Reports Search Engine (MRRSE) has recently updated its massive research catalog by adding a new study, titled “Fragment-based Drug Discovery Market”. The study offers a clear insight about the prevailing trends and innovations happening in the Fragment-based Drug Discovery Market. Readers can further access details about research highlights and executive summary to gain a better idea about this assessment. The market overview covers key industry developments and market opportunity map during the mentioned forecast period. In addition, a holistic view of the entire global market scenario across all the prime regional segments, such as (Regions) has been delivered.

Free | Request a Sample Report or View Summary of Report @ https://www.mrrse.com/sample/1530

extended its tie-up for three more years in order to work upon and develop some effective small molecule remedies. The agreement also has the provision to extend the partnership after the end of three years. Crown Bioscience, Inc., Alveus Pharmaceuticals, Evotec AG, Beactica AB, BioFocus, Emerald BioStructures, Charles River Laboratories International, Inc., Proteros Fragments, Kinetic Discovery, Sprint Bioscience, Sygnature Discovery, and Structure Based Design are some of the key players dominating the global market for fragment-based drug discovery. Among these, Astex Pharmaceuticals and Charles River Laboratories International, Inc. and are the market leaders.

The fragment-based drug discovery market is likely to witness a growth at a steady CAGR of 14.4% from 2015 to 2023 in terms of revenue. The rise in CAGR of fragment-based drug discovery can be credited to the factors such as efficiency, moderate controlling property, and it’s highly competitive nature in the market. The revenue was expected to grow worth US$435.6 mn at the end of 2016, and by the end of 2023, the market is evaluated to reach US$1.15 bn. Based on geographical regions, North American region is dominating the other ones. The market evaluation of the region is anticipated to be around 45.4% of the entire market, by the end of 2023. Even though the statistics are likely to drop as compared to those in 2014, but still the region is expected to dominate without any competition or external obstruction.

Increased Popularity in Biopharmaceutical Industry Fuels the Market Demand for Fragment-based Drug Discovery

As the fragment-based drug discovery technique has been introduced in the market, the industry has experienced a noticeable reduction in cost as well as time, which has fueled its demand in the market. The technique has also been helpful in biophysics, and discovery of weak inhibitors. Some of the recently introduced practices include high-throughput screening and combinational chemistry. These techniques have increased the pace and reduced the cost of fragment-based drug discovery programs. The technique is also anticipated to witness a growth in biopharmaceutical industry. Fragment-based drugs discovery technique have discovered an incredible scope of usage in the biopharmaceuticals. This incorporates large firms, CROs, and educational sectors. These procedures have helped greatly in developing a solutions that would lead to achieve enhanced rate of development essentially finished the regular screening techniques. The technique is also used for the ideation of several other chemical compound. By the end of 2023, the fragment-based drug discovery market is anticipated to draw a revenue worth US$565.2 mn.

However, the demand for fragment-based drug discovery market is anticipated to experience a downfall because of low ability of fragment screening, which happens to be a well-known element in several compounds. End-users are also reluctant to experiment with the technique due to lower rate of efficiency.

Lower than Minimum Efficiency Level to Hamper the Market Growth of Fragment-based Drug Discovery

Although fragment-based drug discovery market is quite developed as compared to previous years, the available solutions are still not very efficient. There are still are4as where the usage of these drugs will results only in inefficient results. This factor is likely to hamper the growth of fragment-based drug market. Moreover, it is also expected to pull down the cost of the drugs too. In spite of having several strict reforms and regulations have been made across the world, related to drug discovery and development, the efficacy and curing capability of the drugs has always been a point of concern. As a result, due to lower efficiency than expected, the fragment-based-drug discovery market growth is likely to be declined.

The global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. The fragment screening segment is further sub-segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques include isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy, fluorescence polarization (FP), differential scanning fluorimetry (DSF), surface plasmon resonance, X-ray crystallography, assay (thermal shift), biolayer interferometry, capillary electrophoresis, mass spectrometry, and others (biochemical assays). The end-use applications encouraging the growth of this market are CROs, biopharmaceutical companies, and academic and research institutions. Geographically, the global fragment-based drug discovery market is divided into regions such as North America, Asia Pacific, Europe, Latin America, and Rest of the World.

North America dominated the global fragment-based drug discovery market due to growing awareness about this sector and the high level of its adoption by pharmaceutical companies. However, in the coming years, the Asia Pacific fragment-based drug discovery market will witness phenomenal growth due to the growing number of research and development activities.

Companies Mentioned in the Global Fragment-Based Drug Discovery Market Report

The important players in the global fragment-based drug discovery market are Astex Pharmaceuticals, Beactica AB, Structure Based Design, Inc., Alveus Pharmaceuticals Pvt. Ltd., Emerald BioStructures, Inc., Evotec AG, Crown Bioscience, Inc., Kinetic Discovery Limited, Sprint Bioscience, Proteros Fragments GmbH, Charles River Laboratories International, Inc., and Sygnature Discovery.

Complete Report Details with Tables and Figures @ https://www.mrrse.com/fragment-based-drug-discovery-market

The global fragment-based drug discovery market has been segmented as follows:

Fragment-Based Drug Discovery Market, by Services Component

Fragment Screening
Biophysical Techniques
Nuclear Magnetic Resonance (NMR) Spectroscopy
Differential scanning Fluorimetry (DSF) Assay (Thermal Shift)
Fluorescence Polarization (FP)
Isothermal Titration Calorimetry (ITC)
X-ray Crystallography
Surface Plasmon Resonance
Biolayer Interferometry
Mass Spectrometry
Capillary Electrophoresis
Others (Biochemical Assays)
Non-biophysical Techniques
Fragment Optimization

Fragment-Based Drug Discovery Market, by End-user

Biopharmaceutical Companies
CROs
Academic and Research Institutions

About Market Research Reports Search Engine (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com

This release was published on openPR.